;PMID: 8032908
;source_file_2925.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:46..101] = [t:46..101]
;2)section:[e:105..123] = [t:105..123]
;3)section:[e:127..235] = [t:127..235]
;4)sentence:[e:239..432] = [t:239..432]
;5)sentence:[e:433..546] = [t:433..546]
;6)sentence:[e:548..676] = [t:548..676]
;7)sentence:[e:677..775] = [t:677..775]
;8)sentence:[e:776..958] = [t:776..958]
;9)sentence:[e:959..1077] = [t:959..1077]
;10)sentence:[e:1078..1114] = [t:1078..1114]
;11)sentence:[e:1115..1286] = [t:1115..1286]
;12)sentence:[e:1287..1430] = [t:1287..1430]
;13)section:[e:1434..1478] = [t:1434..1478]

;section 0 Span:0..40
;Brain Res.  1994 Apr 18;643(1-2):108-14.
(SEC
  (FRAG (NNP:[0..5] Brain) (NNP:[6..9] Res) (.:[9..10] .) (CD:[12..16] 1994)
        (NNP:[17..20] Apr) (CD:[21..23] 18) (::[23..24] ;) (CD:[24..27] 643)
        (-LRB-:[27..28] -LRB-) (NN:[28..31] 1-2) (-RRB-:[31..32] -RRB-)
        (::[32..33] :) (CD:[33..39] 108-14) (.:[39..40] .)))

;sentence 1 Span:46..101
;Cytotoxicity of the cocaine metabolite benzoylecgonine.
(SENT
  (NP-HLN
    (NP (NN:[46..58] Cytotoxicity))
    (PP (IN:[59..61] of)
      (NP
        (NP (DT:[62..65] the) (NN:[66..73] cocaine) (NN:[74..84] metabolite))
        (NP (NN:[85..100] benzoylecgonine))))
    (.:[100..101] .)))

;section 2 Span:105..123
;Lin Y, Leskawa KC.
(SEC
  (FRAG (NNP:[105..108] Lin) (NNP:[109..110] Y) (,:[110..111] ,)
        (NNP:[112..119] Leskawa) (NNP:[120..122] KC) (.:[122..123] .)))

;section 3 Span:127..235
;Department of Anatomical Sciences and Neurobiology, School of Medicine, 
;University of Louisville, KY 40292.
(SEC
  (FRAG (NNP:[127..137] Department) (IN:[138..140] of)
        (NNP:[141..151] Anatomical) (NNP:[152..160] Sciences)
        (CC:[161..164] and) (NNP:[165..177] Neurobiology) (,:[177..178] ,)
        (NNP:[179..185] School) (IN:[186..188] of) (NNP:[189..197] Medicine)
        (,:[197..198] ,) (NNP:[200..210] University) (IN:[211..213] of)
        (NNP:[214..224] Louisville) (,:[224..225] ,) (NNP:[226..228] KY)
        (CD:[229..234] 40292) (.:[234..235] .)))

;sentence 4 Span:239..432
;The NG108-15 and C6 cell lines were used in the present study as neuronal and
; glial models, respectively, to examine the cytotoxicity of the major
;metabolite  of cocaine, benzoylecgonine (BE).
(SENT
  (S
    (NP-SBJ-2 (DT:[239..242] The)
      (NML
        (NML (NN:[243..251] NG108-15)
          (NML-1 (-NONE-:[251..251] *P*)))
        (CC:[252..255] and)
        (NML (NN:[256..258] C6)
          (NML-1 (NN:[259..263] cell) (NNS:[264..269] lines)))))
    (VP (VBD:[270..274] were)
      (VP (VBN:[275..279] used)
        (NP-2 (-NONE-:[279..279] *))
        (PP (IN:[280..282] in)
          (NP (DT:[283..286] the) (JJ:[287..294] present) (NN:[295..300] study)))
        (PP (IN:[301..303] as)
          (NP
            (NP (JJ:[304..312] neuronal)
              (NML-3 (-NONE-:[312..312] *P*)))
            (CC:[313..316] and)
            (NP (JJ:[318..323] glial)
              (NML-3 (NNS:[324..330] models)))))
        (,:[330..331] ,)
        (ADVP (RB:[332..344] respectively))
        (,:[344..345] ,)
        (S-PRP
          (NP-SBJ (-NONE-:[345..345] *))
          (VP (TO:[346..348] to)
            (VP (VB:[349..356] examine)
              (NP
                (NP (DT:[357..360] the) (NN:[361..373] cytotoxicity))
                (PP (IN:[374..376] of)
                  (NP
                    (NP
                      (NP (DT:[377..380] the) (JJ:[381..386] major)
                          (NN:[387..397] metabolite))
                      (PP (IN:[399..401] of)
                        (NP (NN:[402..409] cocaine))))
                    (,:[409..410] ,)
                    (NP
                      (NP (NN:[411..426] benzoylecgonine))
                      (NP (-LRB-:[427..428] -LRB-) (NN:[428..430] BE)
                          (-RRB-:[430..431] -RRB-)))))))))))
    (.:[431..432] .)))

;sentence 5 Span:433..546
;Exposure of both cell types to varying  concentrations of BE resulted in a
;loss of cells from the growth surface.
(SENT
  (S
    (NP-SBJ
      (NP (NN:[433..441] Exposure))
      (PP (IN:[442..444] of)
        (NP (DT:[445..449] both) (NN:[450..454] cell) (NNS:[455..460] types)))
      (PP (TO:[461..463] to)
        (NP
          (NP (VBG:[464..471] varying) (NNS:[473..487] concentrations))
          (PP (IN:[488..490] of)
            (NP (NN:[491..493] BE))))))
    (VP (VBD:[494..502] resulted)
      (PP-CLR (IN:[503..505] in)
        (NP
          (NP (DT:[506..507] a) (NN:[508..512] loss))
          (PP (IN:[513..515] of)
            (NP
              (NP (NNS:[516..521] cells))
              (PP (IN:[522..526] from)
                (NP (DT:[527..530] the) (NN:[531..537] growth)
                    (NN:[538..545] surface))))))))
    (.:[545..546] .)))

;sentence 6 Span:548..676
;Analysis of the unattached cells after such exposure, using a variety of 
;techniques, revealed that these cells were not viable.
(SENT
  (S
    (NP-SBJ
      (NP (NN:[548..556] Analysis))
      (PP (IN:[557..559] of)
        (NP (DT:[560..563] the) (JJ:[564..574] unattached)
            (NNS:[575..580] cells)))
      (PP-TMP (IN:[581..586] after)
        (NP (JJ:[587..591] such) (NN:[592..600] exposure))))
    (,:[600..601] ,)
    (S-MNR
      (NP-SBJ (-NONE-:[601..601] *))
      (VP (VBG:[602..607] using)
        (NP
          (NP (DT:[608..609] a) (NN:[610..617] variety))
          (PP (IN:[618..620] of)
            (NP (NNS:[622..632] techniques))))))
    (,:[632..633] ,)
    (VP (VBD:[634..642] revealed)
      (SBAR (IN:[643..647] that)
        (S
          (NP-SBJ (DT:[648..653] these) (NNS:[654..659] cells))
          (VP (VBD:[660..664] were)
            (ADJP-PRD (RB:[665..668] not) (JJ:[669..675] viable))))))
    (.:[675..676] .)))

;sentence 7 Span:677..775
;Therefore, this effect  could not be ascribed to BE interfering with
;cell-substratum interactions.
(SENT
  (S
    (ADVP (RB:[677..686] Therefore))
    (,:[686..687] ,)
    (NP-SBJ-1 (DT:[688..692] this) (NN:[693..699] effect))
    (VP (MD:[701..706] could) (RB:[707..710] not)
      (VP (VB:[711..713] be)
        (VP (VBN:[714..722] ascribed)
          (NP-1 (-NONE-:[722..722] *))
          (PP (TO:[723..725] to)
            (S-NOM
              (NP-SBJ (NN:[726..728] BE))
              (VP (VBG:[729..740] interfering)
                (PP (IN:[741..745] with)
                  (NP
                    (NML (NN:[746..750] cell) (HYPH:[750..751] -)
                         (NN:[751..761] substratum))
                    (NNS:[762..774] interactions)))))))))
    (.:[774..775] .)))

;sentence 8 Span:776..958
;The  early events in BE cytotoxicity were examined by observing cells
;cultivated on  the stage of an inverted microscope, using differential
;interference contrast  (Nomarski) optics.
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[776..779] The) (JJ:[781..786] early) (NNS:[787..793] events))
      (PP (IN:[794..796] in)
        (NP (NN:[797..799] BE) (NN:[800..812] cytotoxicity))))
    (VP (VBD:[813..817] were)
      (VP (VBN:[818..826] examined)
        (NP-1 (-NONE-:[826..826] *))
        (PP-MNR (IN:[827..829] by)
          (S-NOM
            (NP-SBJ (-NONE-:[829..829] *))
            (VP (VBG:[830..839] observing)
              (NP
                (NP (NNS:[840..845] cells))
                (VP (VBN:[846..856] cultivated)
                  (NP (-NONE-:[856..856] *))
                  (PP (IN:[857..859] on)
                    (NP
                      (NP (DT:[861..864] the) (NN:[865..870] stage))
                      (PP (IN:[871..873] of)
                        (NP (DT:[874..876] an) (VBN:[877..885] inverted)
                            (NN:[886..896] microscope)))))))
              (,:[896..897] ,)
              (S-MNR
                (NP-SBJ (-NONE-:[897..897] *))
                (VP (VBG:[898..903] using)
                  (NP (JJ:[904..916] differential)
                    (NML
                      (NML (NN:[917..929] interference) (NN:[930..938] contrast))
                      (NML (-LRB-:[940..941] -LRB-) (NNP:[941..949] Nomarski)
                           (-RRB-:[949..950] -RRB-)))
                    (NNS:[951..957] optics)))))))))
    (.:[957..958] .)))

;sentence 9 Span:959..1077
;Upon exposure of either cell type to 10 microM BE a  retraction of cellular
;processes could be observed within 30 min.
(SENT
  (S
    (PP (IN:[959..963] Upon)
      (NP
        (NP (NN:[964..972] exposure))
        (PP (IN:[973..975] of)
          (NP (DT:[976..982] either) (NN:[983..987] cell) (NN:[988..992] type)))
        (PP (TO:[993..995] to)
          (NP
            (NML (CD:[996..998] 10) (NN:[999..1005] microM))
            (NN:[1006..1008] BE)))))
    (NP-SBJ-1
      (NP (DT:[1009..1010] a) (NN:[1012..1022] retraction))
      (PP (IN:[1023..1025] of)
        (NP (JJ:[1026..1034] cellular) (NNS:[1035..1044] processes))))
    (VP (MD:[1045..1050] could)
      (VP (VB:[1051..1053] be)
        (VP (VBN:[1054..1062] observed)
          (NP-1 (-NONE-:[1062..1062] *))
          (PP (IN:[1063..1069] within)
            (NP (CD:[1070..1072] 30) (NN:[1073..1076] min))))))
    (.:[1076..1077] .)))

;sentence 10 Span:1078..1114
;Within 6 h  cell death was apparent.
(SENT
  (S
    (PP-TMP (IN:[1078..1084] Within)
      (NP (CD:[1085..1086] 6) (NN:[1087..1088] h)))
    (NP-SBJ (NN:[1090..1094] cell) (NN:[1095..1100] death))
    (VP (VBD:[1101..1104] was)
      (ADJP-PRD (JJ:[1105..1113] apparent)))
    (.:[1113..1114] .)))

;sentence 11 Span:1115..1286
;Similar analyses using 50 microM BE in the growth  medium resulted in similar
;results, except that process retraction could be  observed as early as 15 min
;after exposure.
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1115..1122] Similar) (NNS:[1123..1131] analyses))
      (VP (VBG:[1132..1137] using)
        (NP
          (NML (CD:[1138..1140] 50) (NN:[1141..1147] microM))
          (NN:[1148..1150] BE))
        (PP-LOC (IN:[1151..1153] in)
          (NP (DT:[1154..1157] the) (NN:[1158..1164] growth)
              (NN:[1166..1172] medium)))))
    (VP (VBD:[1173..1181] resulted)
      (PP-CLR (IN:[1182..1184] in)
        (NP (JJ:[1185..1192] similar) (NNS:[1193..1200] results)))
      (,:[1200..1201] ,)
      (PP (IN:[1202..1208] except)
        (SBAR (IN:[1209..1213] that)
          (S
            (NP-SBJ-1 (NN:[1214..1221] process) (NN:[1222..1232] retraction))
            (VP (MD:[1233..1238] could)
              (VP (VB:[1239..1241] be)
                (VP (VBN:[1243..1251] observed)
                  (NP-1 (-NONE-:[1251..1251] *))
                  (ADVP-TMP (RB:[1252..1254] as) (JJ:[1255..1260] early)
                    (PP (IN:[1261..1263] as)
                      (PP-TMP
                        (NP (CD:[1264..1266] 15) (NN:[1267..1270] min))
                        (IN:[1271..1276] after)
                        (NP (NN:[1277..1285] exposure))))))))))))
    (.:[1285..1286] .)))

;sentence 12 Span:1287..1430
;These results demonstrate that the  major metabolite of cocaine,
;benzoylecgonine, is cytotoxic to in vitro models of  neuronal and glial
;cells.
(SENT
  (S
    (NP-SBJ (DT:[1287..1292] These) (NNS:[1293..1300] results))
    (VP (VBP:[1301..1312] demonstrate)
      (SBAR (IN:[1313..1317] that)
        (S
          (NP-SBJ
            (NP
              (NP (DT:[1318..1321] the) (JJ:[1323..1328] major)
                  (NN:[1329..1339] metabolite))
              (PP (IN:[1340..1342] of)
                (NP (NN:[1343..1350] cocaine))))
            (,:[1350..1351] ,)
            (NP (NN:[1352..1367] benzoylecgonine)))
          (,:[1367..1368] ,)
          (VP (VBZ:[1369..1371] is)
            (ADJP-PRD (JJ:[1372..1381] cytotoxic)
              (PP (TO:[1382..1384] to)
                (NP
                  (NP
                    (ADJP (FW:[1385..1387] in) (FW:[1388..1393] vitro))
                    (NNS:[1394..1400] models))
                  (PP (IN:[1401..1403] of)
                    (NP
                      (NP (JJ:[1405..1413] neuronal)
                        (NML-1 (-NONE-:[1413..1413] *P*)))
                      (CC:[1414..1417] and)
                      (NP (JJ:[1418..1423] glial)
                        (NML-1 (NNS:[1424..1429] cells))))))))))))
    (.:[1429..1430] .)))

;section 13 Span:1434..1478
;PMID: 8032908 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1434..1438] PMID) (::[1438..1439] :) (CD:[1440..1447] 8032908)
        (NN:[1448..1449] -LSB-) (NNP:[1449..1455] PubMed) (::[1456..1457] -)
        (NN:[1458..1465] indexed) (IN:[1466..1469] for)
        (NNP:[1470..1477] MEDLINE) (-RRB-:[1477..1478] -RSB-)))
